Cancer Epidemiology, Biomarkers & Prevention

IntroductionBRCA1/2 alterations are increasingly recognized as biologically and clinically relevant features in prostate cancer, yet the prognostic and therapeutic significance of zygosity status remains uncertain. Understanding differences between monoallelic and biallelic inactivation may refine risk stratification and guide therapeutic decision-making. Materials and MethodsA retrospective, desk-based observational analysis was performed using publicly accessible datasets from TCGA-PRAD (primary disease) and SU2C/PCF (metastatic disease). BRCA1/2 status was categorized as wild-type, monoallelic, or biallelic based on mutation, copy-number, and loss-of-heterozygosity profiles. Overall survival was evaluated using Kaplan-Meier estimates and Cox models. Systemic therapy outcomes were assessed by treatment class, incorporating exploratory interaction tests. ResultsIn TCGA-PRAD (n=300), OS did not significantly differ by zygosity (global log-rank p=0.45), with median OS of 80.0 months (wild-type), 78.0 months (monoallelic), and 55.0 months (biallelic). In SU2C/PCF (n=200), zygosity stratified outcomes significantly (global log-rank p=0.04): median OS was 22.0 months (wild-type), 14.0 months (monoallelic), and 16.0 months (biallelic). Treatment analyses showed ARSI exposure improved OS in wild-type disease (HR 0.60; 95% CI 0.38-0.95), while interaction testing suggested potential heterogeneity without statistical confirmation (interaction p=0.092). PARP inhibitor exposure showed directionally favorable HRs in wild-type and monoallelic groups but no significant interaction (interaction p=0.757). No therapy class demonstrated consistent effect modification by zygosity. ConclusionBRCA1/2 zygosity shows prognostic relevance in metastatic prostate cancer but not clearly in primary disease. While zygosity did not consistently modify systemic therapy associations in this dataset, findings support zygosity-aware reporting as a practical tool for molecular stratification and future research design.

ImportancePersistent racial and ethnic disparities in breast and prostate cancer mortality are well documented. Most prior studies emphasize between-group differences and rely on population averages or single composite measures of social disadvantage, which can obscure high-need communities within groups. How socio-behavioral determinants of health vary within groups across local gradients of cancer mortality remains incompletely characterized. A framework that combines race- and cancer-specific mortality with local, domain-level socio-behavioral profiles may help identify where burden is greatest and which specific barriers warrant prioritization. ObjectiveTo determine how socio-behavioral risk relates to breast and prostate cancer mortality within racial and ethnic groups and to characterize domain-specific behavioral profiles across low-, moderate- and high-mortality counties to inform targeted, equity-oriented cancer control strategies. DesignCross-sectional study of U.S. counties. Setting United States, county-level analysis. Participants3,141 U.S. counties, stratified within Non-Hispanic White, Non-Hispanic Black, and Hispanic populations. ExposuresCounty-level socio-behavioral determinants of health measured using a composite index comprising seven domains: community solidarity; education, health literacy, and digital connectivity; quality of care; housing and environmental risk; economic livelihoods; lifestyle behaviors; and touchpoints with care. Main outcomes and measuresRace/ethnicity-specific, age-adjusted breast and prostate cancer mortality rates (2018-2022) and county-level socio-behavioral risk scores. Counties were grouped into mortality tertiles within each race/ethnicity-by-cancer-stratum. ResultsAcross groups, higher socio-behavioral risk was associated with higher breast and prostate cancer mortality. For breast cancer, socio-behavioral risk increased monotonically across mortality tertiles for all groups, with the largest within-group increases among Hispanic and Non-Hispanic Black women. For prostate cancer, risk generally increased across mortality tertiles for all groups. Although Hispanic populations had lower population-average mortality, high-mortality Hispanic counties exhibited pronounced risk in lifestyle behaviors, economic livelihoods, and touchpoints with care. Domain patterns associated with high mortality varied by race, ethnicity, and cancer type, with touchpoints with care and economic livelihoods consistently prominent. Conclusions and relevanceWithin-group heterogeneity in socio-behavioral risk is substantial across U.S. counties. Linking population-specific, domain-level socio-behavioral profiles to cancer mortality may support more precise and equity-oriented cancer control strategies than reliance on group averages or composite indices. Key pointsO_ST_ABSQuestionC_ST_ABSWithin racial and ethnic groups, how do socio-behavioral determinants of health vary across US counties with low, moderate, and high breast and prostate cancer mortality? FindingsIn this cross-sectional study, higher county-level socio-behavioral risk was associated with higher breast and prostate cancer mortality across racial and ethnic groups. Race/ethnicity-specific, domain-level profiles revealed within-group heterogeneity, including persistently elevated risk among Non-Hispanic Black populations and pronounced domain-specific gaps in high-mortality Hispanic counties. MeaningLinking population-specific socio-behavioral profiles to local cancer mortality can guide more precise and equity-oriented prioritization of intervention domains and geographies than reliance on group averages or composite indices.

IntroductionSporadic colorectal cancer (CRC) remains a significant driver of worldwide morbidity and mortality. Environmental factors associated with CRC are increasingly well-described and now include generalized colonic dysbiosis and individual enteric bacteria. Clostridioides difficile is one such species, with recent mouse model work suggesting prolonged exposure to C. difficile toxin B is conducive to colonic tumorigenesis. However, there is a dearth of real-world human evidence linking C. difficile infection and CRC. MethodsHerein, we analyzed a multicenter, longitudinal, Electronic Health Record (EHR)-based dataset to test the association between C. difficile test positivity and the risk for incident CRC utilizing unadjusted and multivariable (controlled for clinical conditions independently associated with CRC development) Cox proportional hazard modeling to compare C. difficile exposed and non-exposed cohorts ResultsWe found that individuals who tested recurrently positive for C. difficile had a significantly increased risk for incident CRC (aHR 2.05 [95% CI 1.27-3.29]) compared with those who tested positive only once (aHR 0.70 [0.45-1.10]) or never. Furthermore, we found potential trends that the effect of C. difficile test positivity on the risk for incident CRC was stronger amongst females compared with males. ImportanceThese findings help translate emerging mouse model work on C. difficile-influenced colorectal tumorigenesis and lay groundwork for more substantial human investigations into this connection. These findings also may begin to help guide the personalized deployment of novel fecal microbiota-based therapies designed to interrupt the life cycle of C. difficile within the gut of human hosts and, potentially, prevent long-term health sequelae of chronic C. difficile infection.

BackgroundHelicobacter pylori infection accounts for 98% of gastric cancer (GC) cases in Japan. Since 2013, the nationwide expansion of H. pylori eradication therapy to chronic gastritis patients has created a unique opportunity to evaluate its population-level impact on GC primary prevention. However, short-term reductions in GC deaths are difficult to interpret given the long natural history of gastric carcinogenesis. This study aimed to assess the early impact of population-level eradication on GC deaths. MethodsWe applied a two-layer analytic framework consisting of a counterfactual analysis comparing observed GC deaths during 2013-2021 with expected GC deaths had eradication uptake remained at pre-2013 levels. This was combined with a structured, time-dependent, multilayer state-transition model to estimate GC deaths prevented by eradication using GC incidence integrated with age-dependent H. pylori prevalence. ResultsObserved GC deaths declined from 48,632 in 2013 to 41,624 in 2021, whereas counterfactual GC deaths declined more modestly, from 49,794 to 45,654. The divergence between observed and counterfactual GC deaths widened steadily from 1,162 in 2013 to 4,030 in 2021. Model-based estimates indicated that eradication prevented 1,427 GC deaths during 2013-2021, with annual GC deaths prevented increasing from 17 in 2015 to 417 in 2021, particularly among adults aged 50-79. ConclusionsThis study demonstrates that H. pylori eradication has already contributed to a 10.4% reduction in GC deaths in Japan by 2021, with annual expansion of primary prevention effects. This framework supports evidence-based evaluation of short-term reductions in GC deaths attributable to H. pylori eradication in high-prevalence settings.

Aim and ObjectivesThe study aimed to evaluate the effectiveness of titanium inserts for interdental papilla reconstruction, comparing it with the Han and Takei technique using subepithelial connective tissue grafts. The objectives included assessing the black triangle height, papilla height and papilla presence index (PPI) at baseline, 1 month and 3 months postoperatively along with the evaluation of Early Wound Healing Score (EHS) during the first week of post operative healing period. Patients and MethodsThis single-blind randomized clinical trial included systemically healthy individuals aged 18-35 years with Nordland and Tarnows Class I-III papillary loss. A total of 18 participants were randomly assigned to either test group or control group. Clinical parameters were measured pre- and post-operatively at specified intervals. Both groups received standard presurgical care and postoperative follow-up. The surgical protocol for the test group involved titanium insert placement in the interdental bone, while the control group received a connective tissue graft using the Han and Takei method. ResultsBoth groups showed significant intragroup improvements in all parameters from baseline to 1 and 3 months (p<0.05). However, intergroup comparisons showed no significant differences at most time points, except at 3 months for PPI, where the control group showed significantly better results (p=0.04). EHS scores were not significant between the groups. ConclusionTitanium inserts and CTG both demonstrated clinical effectiveness in enhancing interdental papilla dimensions. These findings support the titanium insert as a viable, less invasive alternative, offering clinicians a practical option for esthetic papilla reconstruction.

BackgroundPancreatic ductal adenocarcinoma is one of the most aggressive and lethal malignancies of the gastrointestinal tract. The poor prognosis is largely attributed to late-stage diagnosis, pronounced tumor heterogeneity, and limited therapeutic efficacy. These challenges underscore the urgent need for the identification of robust molecular biomarkers and novel therapeutic targets. MethodsGene expression data from a total of 146 pancreatic tissue samples, comprising 72 normal and 74 tumor specimens obtained from the Pan-Cancer Atlas(TCGA) were analyzed. Differential gene expression analysis was conducted using the DESeq2 package, followed by functional enrichment analysis based on GO and KEGG. A classification model was developed using the XGBoost algorithm and evaluated through 500 bootstrapping iterations and 5-fold cross-validation to ensure robustness and generalizability. Model interpretability was assessed using SHAP (SHapley Additive exPlanations) values to identify genes with the highest predictive contribution. ResultsA comprehensive transcriptomic analysis revealed significant dysregulation of multiple genes between normal and tumor pancreatic tissues. Genes such as GJB3, S100A2, MSLN, and SLC2A1 were notably overexpressed, whereas DEFA6, APOB, and RBP2 exhibited marked downregulation, indicative of impaired exocrine function and aberrant epithelial reprogramming. The XGBoost classification model achieved an average area under the curve (AUC) of 0.9868 and an overall accuracy of 98.6%. SHAP (SHapley Additive exPlanations) analysis identified GJB3, LINC02086, and TSPAN1 as key predictive features. Six genes were concurrently identified as differentially expressed and highly influential within the model, supporting their potential utility as robust biomarkers for pancreatic tumor characterization. ConclusionsPancreatic ductal adenocarcinoma is marked by extensive transcriptomic reprogramming. The integration of differential gene expression analysis with interpretable machine learning enabled the identification of a molecular signature with potential diagnostic and therapeutic relevance.

BackgroundThe genetic architecture of Breast Cancer (BC) in Arab populations remains largely understudied, limiting the precision of current prevention and screening programs. The Emirati Genome Program (EGP), one of the worlds first nation-wide sequencing initiatives, offers an unprecedented opportunity to delineate inherited BC risk across an entire population. MethodsWe analyzed 436,780 EGP individuals, including 229,309 women, integrating whole-genome sequencing (WGS) with electronic health records (EHRs). We quantified the prevalence and penetrance of pathogenic and likely pathogenic (P/LP) variants across 13 NCCN-recommended BC genes, evaluated the performance of established polygenic risk scores (PRS), and reconstructed >48,000 pedigrees to measure familial aggregation. ResultsP/LP variants were identified in 0.84% of women, accounting for 5.2% of BC cases (mean age of 45.9{+/-}11.1 years). Highly penetrant BRCA1 c.4065_4068del (p.Asn1355fs) and BRCA2 c.2808_2811del (p.Ala938Profs) variants showed age-specific cumulative risks of 37.6% and 31% by age 60, respectively, and allele frequencies up to tenfold higher in the Emirati population than in global reference datasets. The European-derived PRS model (PGS000004) demonstrated strong performance, advancing 10-year BC risk onset by a decade for women in the top decile. Family-based PRS discriminated affected from unaffected individuals, revealing higher polygenic risk even within sister pairs. Integration of monogenic, polygenic, and familial data defined a national framework for risk stratification, identifying disease-free women potentially eligible for targeted prevention. ConclusionsNation-scale genome sequencing reveals, for the first time, the comprehensive landscape of inherited BC susceptibility within a Middle Eastern population. The integration of monogenic, polygenic, and familial data establishes a national framework for genomic risk stratification--transforming population genomics into a foundation for precision prevention and early detection in the UAE and beyond.

Chromosome 5p15.33 harbors several independent association signals which demonstrate antagonistic pleiotropy across cancer types, with causal mechanisms largely unresolved. To identify functional variants and enhancer elements at this locus, we performed statistical fine-mapping followed by massively parallel reporter assays (MPRA) and proliferation based CRISPRi screens. This approach identified eight multi-cancer functional variants (MCFVs) across three GWAS signals. Targeting rs421629 (part of the CLPTM1L signal marked by rs465498) with CRISPRi revealed opposing effects on TERT expression in pancreatic versus lung cancer cells, consistent with the antagonistic pleiotropy observed for this signal. Furthermore, CRISPRi nominated an intronic CLPTM1L variable number tandem repeat (VNTR) as a potent enhancer. Long-read sequencing established VNTR polymorphisms as potential causal variants for the rs465498 signal. We showed that Hippo-pathway transcription factors mediate VNTR enhancer activity in lung and pancreatic cancer cells. Together, these findings indicate that cancer susceptibility at 5p15.33 may be mediated by both SNPs and VNTRs and provide an integrated framework for resolving complex pleiotropic loci.

Background and ObjectivePatients with upper urinary tract urothelial carcinoma (UTUC) undergoing radical surgery are at high risk of developing intravesical recurrences (IVR). The biology of IVR after surgery for UTUC is poorly understood, and urine markers to replace cystoscopic surveillance of the bladder are lacking. Here, we characterized the genomic landscape of UTUC and paired IVR to discover therapeutic targets and identify diagnostic markers for IVR. MethodsWe performed targeted next-generation DNA-sequencing of 571 genes in a cohort of 276 retrospectively and 138 prospectively enrolled UTUC patients who received radical surgery. Clonality and evolution were assessed in 79 paired UTUC-IVR cases. Key Findings and LimitationsMutations in TERT (72%) and FGFR3 (50%) were highly prevalent in UTUC, while mutations in KMT2C were associated with reduced risk of IVR. The mutually exclusive mutational profile of UTUC revealed five genomic subtypes with distinct clinicopathological and molecular characteristics, but none were associated with elevated IVR risk. Clonal evolution of paired UTUC-IVR occurred in 92% of cases via four evolutionary paths, with FGFR3 as a key driver in the largest path (36%). Additionally, hotspot mutations in the TERT promoter, and FGFR3 and HRAS genes were identified as potential markers for noninvasive surveillance by urine testing. Limitations include cohort heterogeneity and the selected gene-targeted sequencing approach. Conclusions and Clinical ImplicationsThe high FGFR3 mutation rate in UTUC and its association with IVR development support anti-FGFR targeted therapy to reduce IVR risk. The clonal relationship between UTUC and IVR underscores the potential for patient-friendly noninvasive urine tests for surveillance after radical surgery. SummaryUpper urinary tract urothelial carcinoma (UTUC) is a rare cancer with a high recurrence rate after surgery. We found that the FGFR3 gene is a potential therapeutic target to reduce the risk of recurrence, while recurrent mutations in TERT, FGFR3 and HRAS could serve as potential markers for noninvasive surveillance by urine testing after surgery for UTUC.

ObjectiveTo evaluate risk of early-onset dementia (EOD) after diagnosis of cancer among Medicaid beneficiaries. DesignLongitudinal observational study of Medicaid enrollment, inpatient, and outpatient claims data from 26 states and Washington, DC, 2001-2019. MethodsBeneficiaries aged 18-64 with [&ge;]6 months of enrollment were matched 1:1 on cancer status (lung, colon, breast, prostate) by age, sex, race, year and state. We estimated the weighted cumulative incidence functions of EOD at 1, 2, and 5 years after cancer diagnosis using the Aalen-Johansen estimator to account for the competing risk of death and cluster stratified analyses to account for matching. We calculated the corresponding risk differences (RD) and 95% confidence intervals (CI) using the 2.5th and 97.5th percentile of point estimates from 500 bootstrap resamples. ResultsThe 5-year risk of EOD was 4.7% (95%CI: 4.5,5.0) and 4.7% (95%CI: 4.4, 4.9) among those with and without lung cancer, respectively (RD:0.08; 95%CI: -0.27,0.42). The 5-year risk of EOD was 4.1% (95%CI: 3.8, 4.4) and 3.9% (95%CI:3.7,4.3) among those with and without colon cancer, respectively, (RD 0.18; 95%CI: -0.25,0.55). The 5-year risk of EOD was 3.0% (95%CI: 2.8,3.1) and 2.9% (95%CI: 2.7,3.0) among those with and without breast cancer, respectively, (RD 0.10; 95%CI: -0.14,0.43). The 5-year risk of EOD was 4.6% (95%CI: 4.3,4.9) and 5.3% (95%CI: 4.9,5.7) among those with and without prostate cancer, respectively; those with prostate cancer had a lower EOD risk (RD -0.66; 95%CI: -1.2,-0.16). ConclusionsEOD incidence peaked at 4-5% among beneficiaries with and without cancer. Diagnosis of lung, colon, breast and prostate cancers were not strongly associated with EOD within 5 years. Additional work is needed to identify risk factors for EOD.

BackgroundTamoxifen is a cornerstone of endocrine treatment for hormone receptor-positive breast cancer, reducing recurrence and breast cancer-specific mortality. However, its use is associated with a small, yet clinically relevant, increase in uterine cancer. As diagnosis of this cancer remains symptom-triggered, it is essential for patients to be aware of this risk and report symptoms promptly for optimal outcomes. We therefore assessed risk awareness among breast cancer survivors while exploring their attitudes towards potential future endometrial surveillance strategies. MethodsOver a 10-month period, a web-based survey was conducted among breast cancer survivors with/without tamoxifen treatment. The mixed-format questionnaire included closed-ended questions and optional free-text comments. Quantitative data were summarized descriptively and analyzed statistically; qualitative responses were reviewed thematically to contextualize survey findings. ResultsOf 163 respondents, 154 breast cancer survivors were included in the analysis, 128 of whom had received tamoxifen. Among tamoxifen-associated participants, 60% reported insufficient awareness of the associated uterine cancer risk, and half expressed uncertainty about the adequacy of the current symptom-triggered endometrial evaluation. Despite this, acceptance of tamoxifen therapy was high; only one patient declined treatment over concerns about side effects. Almost all participants (96%) were willing to adopt endometrial surveillance methods, if developed and validated. ConclusionAs evaluation of tamoxifen-associated uterine pathology is symptom-triggered, our data highlight the need for improved and standardized risk communication to promote timely symptom recognition, reporting, and diagnostic evaluation. Moreover, our findings support incorporating patient-reported preferences into the development of future endometrial detection strategies to improve survivorship care.

Multi-cancer early detection (MCED) tests can detect several cancer types and stages. We previously developed a methylation and protein (MP V1) MCED classifier. In this study, we present a refined MP V2 classifier, developed by evaluating model architectures that improved performance in prospectively enrolled case-control cohorts under standard testing conditions. The newly developed MP V2 classifier was trained to be more generalizable and achieve increased early-stage sensitivity at a target specificity of [&ge;]97.0%. MP V1 and MP V2 classifier performances were compared using a previously described test set, and MP V2 performance was also evaluated in a new independent clinical validation set. Compared to MP V1, the MP V2 classifier demonstrated a 7.3% increase in overall sensitivity, with sensitivity increases of 7.6%, 9.2%, and 8.3% for stages I, II, and stages I/II, respectively, in the intended use (breast and prostate cancers excluded) test set. In an independent validation intended use set, the MP V2 classifier showed an overall sensitivity of 55.6%, with sensitivities of 26.8%, 42.9%, and 34.8% for stages I, II, and stages I/II, respectively. In a case-control setting, the MP V2 classifier offered improved sensitivity for early-stage cancers at a lower specificity target.

While most individuals with familial medullary thyroid carcinoma (fMTC) carry RET mutations, in some instances the causative mutations remain unknown. We studied two related families with RET-negative fMTC in 21 affected individuals through linkage analysis, exome/genome sequencing, and high-density array comparative genomic hybridization. We identified a novel heterozygous 40kb intragenic SLC30A9 deletion which segregated with the disease in all affected individuals. The mutant transcript escaped nonsense-mediated decay and resulted in the production of N-terminally truncated proteins via translation reinitiation from in-frame AUG codons located downstream of the deletion. These proteins showed increased stability and their expression in an MTC cell line increased cell proliferation and clonogenic capacity, supporting an oncogenic role. These findings expand the genetic background of fMTC beyond RET mutations and implicate translation reinitiation in the etiology of cancer susceptibility syndromes secondary to structural genomic variants.

PurposePrognosis in metastatic non-seminomatous germ cell tumors (mNSGCT) is currently guided by the IGCCCG classification, which incorporates tumor markers, organs involved with metastatic disease, and primary site but not histologic subtype. We aimed to evaluate whether specific histological components provide additional prognostic information in a large international mNSGCT cohort. Patient and MethodsWe analyzed clinical, pathologic, and outcome data from 662 patients with mNSGCT across multiple international centers. Cox regression and multivariable stepwise models were used to evaluate the impact of age, tumor histology, serum markers, primary site of disease, chemotherapy, IGCCCG, and post-chemotherapy surgery on overall survival. Analyses were performed using both complete-case and imputed datasets to account for missing values. ResultsThe presence of any percentage of embryonal carcinoma (EC) was independently associated with improved overall survival HR 0.603 (95% CI: 0.37-0.98, p=0.040), whereas yolk sac tumor (YST) predicted worse prognosis in complete-case analysis HR 2.27 (95% CI: 1.43 - 3.61 p = 0.001). Choriocarcinoma was also associated with a HR 1.58 (95% CI: 1.08 - 2.32 p= 0.019) adverse outcomes. IGCCCG risk classification remained a strong predictor of mortality HR up to 8.9 for Poor vs Good risk, (95% CI: 4.63 - 17.09 p < 0.001), but histologic components added significant independent prognostic value. Post-chemotherapy retroperitoneal lymph node dissection (RPLND) conferred a substantial survival benefit HR 0.44 (95% CI: 0.258 - 0.754 p=0.003). Interestingly, teratoma was not associated with mortality but was linked to younger age, testicular primaries, and higher likelihood of residual disease requiring surgery. ConclusionsHistological composition, particularly the presence of EC or YST, has a significant and independent impact on survival in mNSGCT, beyond established risk classifications. Integration of histological subtypes may enhance prognostic accuracy and guide individualized treatment strategies in advanced germ cell tumors.

Gastrointestinal (GI) polyposis is a major risk factor for colorectal cancer (CRC) and a defining feature of hereditary polyposis syndromes such as familial adenomatous polyposis (FAP). Therapy-associated polyposis (TAP), however, is a rare and incompletely characterized condition that develops decades after treatment for childhood or young adult cancers (CYAC), most often following abdominopelvic radiation or exposure to alkylating agents. As long-term CYAC survival improves, the burden of late GI toxicity, including markedly elevated risks of polyps, CRC, and secondary cancers, continues to rise, yet the molecular features of TAP remain poorly understood. Here, we present the largest clinicopathological and genomic study of TAP to date, comprising 29 patients diagnosed at a median age of 49 years and a median latency of 29 years after primary cancer therapy. Most patients (78%) had received alkylating agents and exhibited high rates of secondary malignancies. Histopathology revealed mixed polyp subtypes with a predominance of adenomas. Given these features and the presence of family history in a subset of patients, we investigated the possibility of Hereditary Mixed Polyposis Syndrome (HMPS). Whole-genome sequencing excluded HMPS by demonstrating absence of the canonical 40-kb GREM1 duplication and lack of consistent GREM1 overexpression. Comparative genomic analysis revealed that TAP adenomas exhibit more extensive genome fragmentation and a higher burden of large structural variants than FAP adenomas. Mutational signature profiling identified strong contributions from age-associated signatures (SBS1, SBS5) and a strong, pervasive contribution of the alkylating-agent signature SBS25, even in samples lacking matched normal tissue, whereas platinum-associated SBS31 was minimal. Patient-derived organoids from TAP adenomas showed impaired differentiation, suggesting persistent therapy-induced stem cell dysfunction. Together, these findings define TAP as a distinct polyposis syndrome marked by heterogeneous histology, long latency, profound structural genomic injury, and chemotherapy-specific mutational scars. This work supports early and tailored GI surveillance for CYAC survivors and provides mechanistic insight into the long-term consequences of cytotoxic therapy on intestinal epithelial homeostasis.

BackgroundNo randomized clinical trial comparing the most established new modalities of treatment for patients with localized prostate cancer has been published, and there is scarce comparative effectiveness research assessing Patient-Reported Outcome Measures (PROMs). Objectiveto compare the impact of active surveillance, robot-assisted radical prostatectomy (RARP), Intensity-modulated radiotherapy (IMRT), and real-time brachytherapy on patients, through PROMs, from pre-treatment to five years after diagnosis of localized prostate cancer. MethodsProspective observational study (ClinicalTrials.gov, NCT05523856) of 566 male patients diagnosed in 2014 to 2021 with clinically localized prostate cancer (50-75 years old; stage cT1 or cT2, N0/Nx and M0/Mx; Gleason [&le;] 6 or 7 (if 3 + 4 with T1c); and PSA [&le;] 10 ng/ml) and followed until 2019-2026. The Expanded Prostate Cancer Index Composite (EPIC-26) measures urinary incontinence, urinary irritative/obstructive symptoms, sexual, bowel and hormonal domains. EPIC-26 was centrally administered via telephone interviews before treatment and then annually after treatment. Generalized estimating equation (GEE) models were constructed with overlap propensity score-based weights and adjusted by age and clinical tumor stage. ResultsWeighted results of adjusted GEE models showed significant declines for sexual health during the 5yr in all treatment groups (ranging from -19.8 to -27.6), but this worsening appeared earlier in those of active treatment (RARP, IMRT and brachytherapy) than in active surveillance. The RARP group presented the greatest deterioration in urinary incontinence (-28.5 vs -11.7 in active surveillance), while the greatest impairment in bowel symptoms was observed in both radiotherapy groups (around -3 vs +0.3 in active surveillance). ConclusionOur findings provide detailed novel evidence, measured over 5 yr, on the long-term impact of disease and treatment on patients with localized prostate cancer. While all treatment groups showed large sexual deterioration overtime, important differences in urinary incontinence (highest after RARP) and bowel symptoms (after IMRT and brachytherapy) persisted. These findings can inform patients during shared decision-making on the alignment between localized prostate cancer treatment choices and their priorities.

Genome wide association studies (GWAS), combined with fine-mapping have identified 196 independent signals associated with breast cancer risk. Deciphering the functional basis of these associations can inform our understanding of the biology and aetiology of breast cancer. Decoding GWAS risk associations is challenging due to linkage disequilibrium between variants and because most variants map to non-coding regions, influencing breast cancer risk via cis-regulatory mechanisms that modulate the expression of target genes. To identify the functional variants driving breast cancer risk associations, we carried out a lentivirus-based massively parallel reporter assay (lentiMPRA) to screen 5,116 credible causal variants across these signals. We identified 709 variants mapping to 140 risk regions, that are associated with significant variation between REF and ALT alleles. A follow-up investigation at 14q32.11 revealed rs7153397 may impact expression of CCDC88C to influence both breast cancer risk and prognosis. These findings provide a prioritised set of functional variants for downstream analyses, advancing our understanding of breast cancer risk mechanisms.

BackgroundPeople with HIV (PWH) experience higher cancer-specific mortality and may have worse surgical outcomes than people without HIV (PWoH), though the limited prior evidence largely predates the treat-all antiretroviral therapy (ART) era. We examined postoperative outcomes among PWH and PWoH enrolled in Medicaid in 26 states and Washington, D.C. from 2001-2021. MethodsWe identified the first inpatient/outpatient surgery for anal, bladder, breast, colorectal, female genitourinary, gastroesophageal, head and neck, kidney, liver, lung, ovarian, or pancreatic cancer among adults with continuous enrollment for at least 6 months pre- and 3 months post-surgery. Outcomes included length of stay (LOS), 7- and 30-day readmissions (overall and unplanned), emergency department (ED) use, surgical site infection (SSI), and mortality (30-day, 90-day, 1-year, 5-year). Linear, logistic, and Cox proportional hazards models were adjusted for demographics, comorbidities, cancer type, surgical setting and risk, metastasis, and preoperative treatment (radiation/chemotherapy). ResultsAmong 198,535 beneficiaries undergoing cancer surgery, 4,199 (2.1%) were PWH. PWH were more likely to have inpatient procedures (72.6% vs. 56.4%). Compared to PWoH, PWH had more utilization with longer LOS (7.0 vs. 4.3 days; adjusted mean difference [aMD] = 0.79, 95% CI = 0.60-0.99), extended hospital stays (13.8 vs. 7.4 days; aMD=2.76, 95% CI= 2.42-3.10), and more ED visits (0.82 vs. 0.55 per 90 days; aMD = 0.19, 95% CI = 0.15-0.23). There were no significant differences in readmission, SSI, or 30-day mortality. PWH had higher 90-day mortality (3.2% vs. 1.8%; adjusted odds ratio [aOR] = 1.31, 95% CI = 1.08-1.57), though this was attenuated in the treat-all ART era (2012 - 2021). Results were similar for inpatient surgeries and most common cancer types. PWH had an elevated hazard of 1-year and 5-year mortality post-surgery with an adjusted hazard ratio [aHR] of 1.31 (95% CI = 1.17-1.46) and 1.22 (95% CI= 1.14-1.31), respectively, especially for colorectal cancer (1-year aHR= 1.53, 95% CI=1.24-1.88; 5-year aHR=1.32, 95% CI= 1.14-1.52). ConclusionsPWH had higher post-cancer surgery utilization but similar short-term complications, which supports current guidelines to provide standard cancer care for PWH. More work is needed to elucidate the factors contributing to higher long-term mortality among PWH.

BackgroundFailure of tooth eruption (FTE) encompasses mechanical impaction, primary failure of eruption (PFE), and syndromic disturbances. Since the seminal review by Suri et al. (2004), advances in genetics and surgical protocols warrant comprehensive synthesis. ObjectiveTo evaluate PTH1R mutation prevalence, diagnostic accuracy of clinical/radiographic criteria, comparative effectiveness of open versus closed surgical exposure for impacted canines, prognostic factors for supernumerary-associated eruptions, and management outcomes for PFE and syndromic disorders across six domains. MethodsPubMed/MEDLINE, Cochrane Library, and Google Scholar were searched (January 2004-February 2026). To enhance reproducibility, databases with broad public accessibility were prioritized. Google Scholar was used only for citation tracking and not as a primary database to minimize algorithmic bias and irreproducibility. PRISMA 2020 guidelines were followed. Protocol registered on OSF (DOI: 10.17605/OSF.IO/R5X76). Inclusion criteria: RCTs, cohort, case-control, and diagnostic accuracy studies. Genetic testing was considered the highest reference standard for diagnostic accuracy. Risk of bias assessed using ROBINS-I, QUADAS-2, and RoB 2.0. Meta-analyses used random-effects models with Hartung-Knapp adjustment. Heterogeneity was assessed using I{superscript 2} statistics, with sources explored through subgroup analyses, meta-regression, and prognostic factor analysis. GRADE evaluated evidence quality. Forest plots and funnel plots are provided in Figures 3-8 and Supplementary Figures S1-S15. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=126 SRC="FIGDIR/small/26346646v1_fig3.gif" ALT="Figure 3"> View larger version (10K): org.highwire.dtl.DTLVardef@1d71b0forg.highwire.dtl.DTLVardef@1318309org.highwire.dtl.DTLVardef@1920208org.highwire.dtl.DTLVardef@c36c6f_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 3:C_FLOATNO Forest Plot - Treatment Duration Difference (Closed vs. Open Exposure). Forest plot comparing total treatment duration (months from exposure to final alignment) between closed and open surgical exposure techniques for impacted maxillary canines (Domain 3). Data from 8 studies comprising 1,287 canines. Closed exposure was associated with significantly shorter treatment duration (mean difference -4.7 months; 95% CI: -7.3 to -2.1; p < 0.001). Heterogeneity was moderate to high (I{superscript 2} = 64.1%), partially explained by study design in meta-regression (RCTs vs. cohorts, p = 0.04). The 95% prediction interval (-9.8 to 0.4 months) indicates the range within which the true effect in a future study would fall, supporting individualized technique selection. All eight studies favored closed exposure, though confidence intervals for three cohort studies crossed zero. Study weights ranged from 4.0% to 18.2%. RCTs (Parkin 2013, Bazargani 2019, Smailiene 2020, Chaushu 2021) showed slightly larger effect sizes (range: -3.8 to -6.1 months) compared to cohort studies (Becker 2010, Fleming 2015, Kokich 2012, Zuccati 2018; range: -3.2 to -6.4 months). Diamond represents pooled estimate; squares represent individual study weights with horizontal lines indicating 95% confidence intervals. C_FIG O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=142 SRC="FIGDIR/small/26346646v1_fig8.gif" ALT="Figure 8"> View larger version (40K): org.highwire.dtl.DTLVardef@42959org.highwire.dtl.DTLVardef@136c662org.highwire.dtl.DTLVardef@11a59e3org.highwire.dtl.DTLVardef@1035b2a_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 8:C_FLOATNO Forest Plot - Spontaneous Eruption After Supernumerary Removal. Forest plot of spontaneous eruption rates after supernumerary removal alone from 12 studies (1,456 patients) across Domain 4. Reported rates ranged from 48% to 68% across studies (I{superscript 2} = 71.2%). High heterogeneity reflects differences in patient age (deciduous vs. mixed vs. permanent dentition), supernumerary morphology (conical vs. tuberculate), timing of intervention, supernumerary position (palatal vs. labial vs. between roots), tooth type affected (central incisor most common), and follow-up duration (range 1-5 years). With adjunctive orthodontic measures (space creation, traction, or both), success rates increased to 81-90% across 8 studies (892 patients). Study weights ranged from 8.4% to 8.9%. Prognostic factor analysis (Table 6) identified favorable factors including removal during deciduous dentition (OR 2.5-5.5), conical supernumerary morphology (OR 3.0-6.5), and incomplete root formation of the permanent incisor (OR 2.5-5.0). Unfavorable factors included tuberculate morphology (OR 0.2-0.4) and complete root formation (OR 0.2-0.5). Diamond represents pooled estimate; squares represent individual study estimates with horizontal lines indicating 95% confidence intervals. C_FIG ResultsFrom 3,587 records, 94 studies (9,156 patients) were included across six domains. Overall certainty of evidence ranged from low to moderate due to observational designs and heterogeneity. Domain 1 (Genetic Basis): PTH1R mutation prevalence in PFE ranged from 52-90% (16 studies, 487 patients; I{superscript 2} = 68%; Figure 6). Heterogeneity reflected differences in familial vs. sporadic cases and referral bias. Population-level prevalence remains unknown. Sixty-three variants identified. Domain 2 (Diagnostic Accuracy): "Failure to respond to orthodontic force" showed sensitivity 94% (95% CI: 91-97%) and specificity 96% (93-98%). "Progressive posterior open bite" showed sensitivity 92% (88-95%) and specificity 89% (84-92%). Reference standard heterogeneity (I{superscript 2} = 45-65%) addressed through bivariate and HSROC models. CBCT provided superior root resorption detection (97% vs. 68%; p < 0.001). Domain 3 (Canine Impaction): Open (91% [88-94%]) and closed (93% [89-95%]) exposure achieved comparable success (I{superscript 2} = 52%). Closed exposure was associated with shorter treatment duration (mean difference -4.7 months [-7.3 to -2.1]; I{superscript 2} = 64%; Figure 3) and lower postoperative pain (-1.9 VAS [-2.6 to -1.2]; I{superscript 2} = 58%; Figure 4). Prediction intervals (-9.8 to 0.4 months) support individualized technique selection. Funnel plots showed no significant publication bias (Figure 7). Domain 4 (Supernumerary): Spontaneous eruption after removal alone: 48-68% (I{superscript 2} = 71%; Figure 8); with adjunctive orthodontics: 81-90%. Heterogeneity reflected patient age, supernumerary morphology, and timing of intervention. Favorable factors: deciduous removal (OR 2.5-5.5), conical morphology (OR 3.0-6.5), incomplete root formation (OR 2.5-5.0). Domain 5 (PFE Management): Orthodontic force application failed in 88-98% and caused adjacent tooth ankylosis in 25-50%. Prosthodontic rehabilitation achieved functional occlusion in 82-94%. Implant success: 85-95%. Meta-analysis not performed due to critical heterogeneity. Domain 6 (Syndromic): Cleidocranial dysplasia alignment: 61-75%. Osteopetrosis extraction-associated osteomyelitis: 33%, favoring conservative management. Narrative synthesis only. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=148 SRC="FIGDIR/small/26346646v1_fig6.gif" ALT="Figure 6"> View larger version (40K): org.highwire.dtl.DTLVardef@15622eborg.highwire.dtl.DTLVardef@e7403org.highwire.dtl.DTLVardef@e27724org.highwire.dtl.DTLVardef@1fbe10a_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 6:C_FLOATNO Forest Plot - PTH1R Mutation Prevalence. Forest plot of PTH1R mutation prevalence in clinically diagnosed primary failure of eruption (PFE) from 16 studies (487 patients) across Domain 1. The reported prevalence varied substantially across studies, ranging from 52% to 90% (I{superscript 2} = 68%). Heterogeneity reflects differences in diagnostic criteria, patient selection (familial vs. sporadic cases), and referral bias. Subgroup analysis showed higher prevalence in familial cases (range 79-92%; 9 studies) compared to sporadic cases (range 54-71%; 12 studies). Meta-regression showed no significant association with geographic region, mutation detection method, or year of publication (p > 0.05 for all). Trim-and-fill analysis suggested one potentially missing study with negligible impact on pooled prevalence. Study weights ranged from 5.7% to 6.8%. The most frequently reported studies include Frazier-Bowers 2010 (0.75, 95% CI: 0.58-0.87), Risom 2013 (0.82, 95% CI: 0.66-0.92), and Park 2025 (0.89, 95% CI: 0.74-0.96). Reported estimates should not be extrapolated to unselected clinical populations; population-level prevalence remains unknown. Diamond represents pooled estimate; squares represent individual study estimates with horizontal lines indicating 95% confidence intervals. C_FIG O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=147 SRC="FIGDIR/small/26346646v1_fig4.gif" ALT="Figure 4"> View larger version (17K): org.highwire.dtl.DTLVardef@1737e7forg.highwire.dtl.DTLVardef@175c6a4org.highwire.dtl.DTLVardef@1446af8org.highwire.dtl.DTLVardef@caff01_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 4:C_FLOATNO Forest Plot - Postoperative Pain Difference (Closed vs. Open Exposure). Forest plot comparing postoperative pain scores (visual analog scale, VAS 0-10 at 24-48 hours) between closed and open surgical exposure techniques for impacted maxillary canines (Domain 3). Data from 5 studies comprising 842 patients. Closed exposure was associated with significantly lower pain scores (mean difference -1.9; 95% CI: -2.6 to -1.2; p < 0.001). Heterogeneity was moderate (I{superscript 2} = 58.2%), reflecting differences in pain measurement timing (24h vs. 48h), analgesic protocols, and study design (RCT vs. cohort). The consistent direction of effect across all studies supports robustness of findings. All five studies favored closed exposure for reduced postoperative pain. Study weights ranged from 17.5% to 22.4%. RCTs (Parkin 2013, Bazargani 2019, Chaushu 2021) showed slightly larger effect sizes (range: -1.8 to -2.4) compared to cohort studies (Becker 2010, Fleming 2015; range: -1.2 to -1.6). Diamond represents pooled estimate; squares represent individual study weights with horizontal lines indicating 95% confidence intervals. C_FIG O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=114 SRC="FIGDIR/small/26346646v1_fig7.gif" ALT="Figure 7"> View larger version (29K): org.highwire.dtl.DTLVardef@12bbffdorg.highwire.dtl.DTLVardef@1497eb8org.highwire.dtl.DTLVardef@1e879eorg.highwire.dtl.DTLVardef@59d3ae_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 7:C_FLOATNO Funnel Plot - Publication Bias for Canine Studies. Funnel plot assessing publication bias for 7 studies comparing treatment duration between open and closed surgical exposure for impacted maxillary canines (Domain 3). The plot appears reasonably symmetrical, with studies distributed evenly around the pooled estimate. Eggers test was non-significant (p = 0.38), suggesting no strong evidence of publication bias for this outcome. Each circle represents an individual study. The funnel shape represents the pseudo 95% confidence interval limits. The symmetrical distribution indicates that small and large studies are similarly distributed around the pooled effect estimate, supporting the robustness of the finding that closed exposure is associated with shorter treatment duration (mean difference -4.7 months; 95% CI: -7.3 to -2.1). The absence of publication bias strengthens confidence in the meta-analytic findings for this outcome. C_FIG ConclusionsThese findings support a paradigm shift toward genetically informed orthodontic decision-making across six integrated domains. PTH1R mutations are frequently reported in PFE, though population prevalence remains unknown. Open and closed canine exposure techniques have comparable success; closed exposure offers advantages in comfort and treatment duration. Early supernumerary intervention improves outcomes. Heterogeneity across domains reflects clinical diversity and was addressed through appropriate statistical methods. Orthodontic forces should be avoided in confirmed PFE. RegistrationOpen Science Framework (DOI: 10.17605/OSF.IO/R5X76)

BackgroundGlyphosate-based herbicides are among the most widely used agricultural chemicals globally. Concerns regarding their carcinogenic potential, particularly in relation to non-Hodgkins lymphoma (NHL), persist despite multiple prior systematic reviews and meta-analyses. However, these reviews have demonstrated important methodological limitations and inconsistent analytic decisions, limiting confidence in their conclusions. ObjectiveTo conduct a rigorous, up-to-date systematic review and meta-analysis of observational studies examining the association between glyphosate-based herbicide exposure and risk of NHL and its subtypes, while addressing methodological and analytic shortcomings of prior syntheses. MethodsWe searched MEDLINE (1970-February 26, 2026) and EMBASE (inception-February 26, 2026), supplemented by reference list review. Eligible studies included cohort, case-control, and pooled analyses reporting effect estimates (or sufficient data) for glyphosate exposure and NHL incidence. Two reviewers independently assessed risk of bias using the Newcastle-Ottawa Scale (for primary studies) and structured criteria for pooled analyses. Random- and fixed-effects meta-analyses were conducted using inverse-variance methods. Heterogeneity was evaluated using Cochrans Q and I{superscript 2} statistics. Publication bias was assessed using standard and contour-enhanced funnel plots. Sensitivity analyses addressed overlapping cohorts, hazard ratio inclusion, exposure definitions, and model overfitting (events-per-variable considerations). Certainty of evidence was graded using GRADE. ResultsSeventeen publications were identified, representing 20 unique study populations; after accounting for overlap, 10 primary datasets were included in quantitative synthesis. Five studies were assessed as low risk of bias, four as moderate risk, and one as high risk. For ever exposure, the random-effects model across all eligible datasets yielded an odds ratio (OR) of 1.11 (95% CI: 0.98-1.27), with moderate heterogeneity (I{superscript 2}{approx}53%). In sensitivity analyses excluding hazard ratio-only studies and overlapping cohorts, pooled ORs ranged from 1.19 to 1.23, with estimates approaching or reaching statistical significance depending on modeling assumptions. For the highest exposure categories, the random-effects model demonstrated a statistically significant association (OR{approx}1.38; 95% CI: 1.00-1.90), with moderate heterogeneity (I{superscript 2}{approx}61%). Sensitivity analyses excluding selected pooled cohort estimates strengthened the association (OR{approx}1.47; 95% CI: 1.04-2.06). Analyses incorporating alternative cumulative exposure metrics yielded similar significant associations (OR{approx}1.33-1.45) with low or absent residual heterogeneity. Subtype analyses suggested elevated risks particularly for diffuse large B-cell lymphoma and follicular lymphoma in certain datasets. Publication bias assessments revealed evidence of small-study effects in some models, though contour-enhanced analyses suggested that not all asymmetry was attributable to selective publication. Overall certainty of evidence was graded as moderate for highest exposure analyses and low-to-moderate for ever-exposure analyses due to residual heterogeneity and observational design limitations. ConclusionsThis updated synthesis indicates that while associations with ever exposure to glyphosate are modest and sensitive to analytic decisions, higher levels of exposure are consistently associated with increased odds of NHL. Findings are robust across multiple sensitivity analyses addressing overlapping data, exposure classification, and model overfitting. These results support a dose-related association between glyphosate-based herbicide exposure and NHL risk and underscore the need for continued surveillance, improved exposure characterization, and prospective cohort analyses with minimized loss to follow-up and transparent analytic reporting.